Literature DB >> 21102646

Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus.

Marco Arrese1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21102646     DOI： 10.1038/nrendo.2010.173

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Nonalcoholic fatty liver disease and diabetes mellitus.

Authors:  Leon A Adams
Journal:  Endocr Res       Date:  2007       Impact factor: 1.720

2.  Epidemiology and natural history of non-alcoholic steatohepatitis.

Authors:  Curtis K Argo; Stephen H Caldwell
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

3.  Newly diagnosed diabetes mellitus as a risk factor for serious liver disease.

Authors:  Liane Porepa; Joel G Ray; Paula Sanchez-Romeu; Gillian L Booth
Journal:  CMAJ       Date:  2010-06-21       Impact factor: 8.262

4.  Epidemiology of non-alcoholic fatty liver disease.

Authors:  Stefano Bellentani; Federica Scaglioni; Mariano Marino; Giorgio Bedogni
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

Review 5.  Diabetes and liver disease: an ominous association.

Authors:  Simona Moscatiello; Rita Manini; Giulio Marchesini
Journal:  Nutr Metab Cardiovasc Dis       Date:  2007-01       Impact factor: 4.222

Review 6.  Recent concepts in non-alcoholic fatty liver disease.

Authors:  L A Adams; P Angulo
Journal:  Diabet Med       Date:  2005-09       Impact factor: 4.359

Review 7.  The epidemiology of nonalcoholic fatty liver disease: a global perspective.

Authors:  Mariana Lazo; Jeanne M Clark
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

Review 8.  Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).

Authors:  Stefano Bellentani; Mariano Marino
Journal:  Ann Hepatol       Date:  2009       Impact factor: 2.400

Review 9.  Nonalcoholic fatty liver disease in type 2 diabetes mellitus.

Authors:  Kenneth Cusi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

Review 10.  Fatty liver and lipotoxicity.

Authors:  Michael Trauner; Marco Arrese; Martin Wagner
Journal:  Biochim Biophys Acta       Date:  2009-10-24
  10 in total
  9 in total

1.  Long-Term, Fructose-Induced Metabolic Syndrome-Like Condition Is Associated with Higher Metabolism, Reduced Synaptic Plasticity and Cognitive Impairment in Octodon degus.

Authors:  Daniela S Rivera; Carolina B Lindsay; Juan F Codocedo; Laura E Carreño; Daniel Cabrera; Marco A Arrese; Carlos P Vio; Francisco Bozinovic; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2018-04-13       Impact factor: 5.590

2.  Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion.

Authors:  Pablo Quintero; Margarita Pizarro; Nancy Solís; Juan Pablo Arab; Oslando Padilla; Arnoldo Riquelme; Marco Arrese
Journal:  J Physiol Biochem       Date:  2014-05-10       Impact factor: 4.158

3.  Antidiabetic Effect of Methanolic Extract from Berberis julianae Schneid. via Activation of AMP-Activated Protein Kinase in Type 2 Diabetic Mice.

Authors:  Jing Yang; Ping Zhao; Dingrong Wan; Qi Zhou; Chao Wang; Guangwen Shu; Zhinan Mei; Xinzhou Yang
Journal:  Evid Based Complement Alternat Med       Date:  2014-09-02       Impact factor: 2.629

Review 4.  NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment.

Authors:  Ming-Feng Xia; Hua Bian; Xin Gao
Journal:  Front Pharmacol       Date:  2019-08-06       Impact factor: 5.810

5.  Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.

Authors:  Yayoi Nishida; Yasuo Takahashi; Kotoe Tezuka; Hayato Akimoto; Tomohiro Nakayama; Satoshi Asai
Journal:  BMC Pharmacol Toxicol       Date:  2020-04-21       Impact factor: 2.483

6.  Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.

Authors:  Chloe Wong; Clyve Yu Leon Yaow; Cheng Han Ng; Yip Han Chin; Yi Fen Low; Amanda Yuan Ling Lim; Mark Dhinesh Muthiah; Chin Meng Khoo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-11       Impact factor: 5.555

7.  Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats.

Authors:  Wei Wang; Chuang Wang; Xiao-Qin Ding; Ying Pan; Ting-Ting Gu; Ming-Xing Wang; Yang-Liu Liu; Fu-Meng Wang; Shui-Juan Wang; Ling-Dong Kong
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

8.  Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation.

Authors:  Daniel Cabrera; Claudio Cabello-Verrugio; Nancy Solís; Diego San Martín; Catalina Cofré; Margarita Pizarro; Juan Pablo Arab; Johanna Abrigo; Fabián Campos; Betzabé Irigoyen; Gonzalo Carrasco-Avino; Katiuska Bezares; Valentina Riquelme; Arnoldo Riquelme; Marco Arrese; Francisco Barrera
Journal:  Int J Mol Sci       Date:  2018-05-02       Impact factor: 5.923

9.  Reduction of Fat to Muscle Mass Ratio Is Associated with Improvement of Liver Stiffness in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Takafumi Osaka; Yoshitaka Hashimoto; Takuro Okamura; Takuya Fukuda; Masahiro Yamazaki; Masahide Hamaguchi; Michiaki Fukui
Journal:  J Clin Med       Date:  2019-12-09       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.